VISTAGEN THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-69.7M | $-51.4M | $-29.4M | $-59.2M | $-47.8M | $-17.9M | $-20.8M | $-24.6M |
| Depreciation & Amortization | $199.0K | $150.0K | $127.0K | $130.0K | $153.5K | $117.6K | $103.1K | $91.2K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $4.0M | $4.3M | $2.2M | $3.3M | $3.5M | $2.3M | — | — |
| Net Cash from Operating Activities | $-66.4M | $-42.1M | $-25.8M | $-49.7M | $-45.3M | $-12.1M | $-15.8M | $-14.5M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | $0 | $528.0K | $200.4K | $275.4K | $0 | $174.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-877.0K | $-13.1M | $-61.0K | $-740.0K | $-200.4K | $-275.4K | $0 | $-174.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $31.0M | $3.2M | $128.4M | $-1.0M | $10.5M | $114.1M | $4.0M | $17.4M |
| Net Change in Cash | $-36.3M | $-52.0M | $102.5M | $-51.5M | $-35.0M | $101.8M | $-11.7M | $2.7M |
| Free Cash Flow | — | — | $-25.8M | $-50.2M | $-45.5M | $-12.3M | $-15.8M | $-14.7M |